A69.21 Insurance Policy Changes

ICD-10 A69.21 is officially defined as "Meningitis due to Lyme disease." code A69.21 is referenced in 4 tracked payer policy changes from Independence Blue Cross and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code A69.21 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Dec 29, 2025Medium impact
MA06.006g, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy
Independence Blue Cross Medicare Advantage Policy MA06.006g has been superseded by MA06.006h effective 12/29/2025. New coverage includes: PCR testing for Lyme disease diagnosis in immunodeficient individuals and synovial fluid PCR for Lyme arthritis; five new HCPCS home infusion therapy codes (S9497-S9503); CPT 87475 reclassified from experimental to medically necessary; and CPT 0580U added as experimental/investigational. The iDart Lyme IgG ImmunoBlot kit remains experimental.
Independence Blue Cross · Effective Dec 29, 2025Medium impact
06.02.01l, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy
Independence Blue Cross updated policy 06.02.01l to 06.02.01m, effective 12/29/2025, adding PCR testing as medically necessary for Lyme disease diagnosis in immunodeficient individuals and for synovial fluid testing in Lyme arthritis. Five new HCPCS codes (S9497, S9500, S9501, S9502, S9503) for home infusion therapy at various dosing intervals were added as covered, CPT 87475 was reclassified from experimental to medically necessary, and CPT 0580U was added as experimental/investigational.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Intravenous Antibiotic Therapy and Associated Diagnostic Testing for Lyme Disease
Treatment of Lyme disease consists of oral antibiotics except for neuroborreliosis, Lyme carditis and Lyme arthritis. A 2- to 4-week course of IV antibiotics may be considered medically necessary for neuroborreliosis with objective neurologic complications of documented Lyme disease, and a single 2- to 4-week IV course may be considered for Lyme carditis or for the small subset of well-documented Lyme arthritis that is severe enough to need the rapid response of IV antibiotics. IV antibiotic therapy is considered investigational for conditions such as chronic fatigue syndrome or fibromyalgia without objective evidence of Lyme disease, post-Lyme syndrome, and repeat or prolonged courses longer than 4 weeks.
Independence Blue Cross · Effective Apr 1, 2026Low impact
06.02.01m, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy
Independence Blue Cross updated policy 06.02.01m effective 04/01/2026 to revise the CPT code narrative for 0580U as part of an annual CPT code update. The policy itself—covering Lyme disease diagnosis methods (ELISA, Western blot, PCR) and IV antibiotic therapy criteria—remains substantively unchanged; this is a technical code documentation update with no new billing requirements.

Watch A69.21

Get one email when a payer policy names A69.21, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code A69.21?

There are 4 tracked policy changes affecting code A69.21, including updates from Independence Blue Cross, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code A69.21?

Payers that have issued tracked updates for code A69.21 include: Independence Blue Cross, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code A69.21 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code A69.21. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code A69.21?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA06.006g, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy

06.02.01l, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy

Intravenous Antibiotic Therapy and Associated Diagnostic Testing for Lyme Disease

06.02.01m, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy

What insurance policy changes affect code A69.21?

Which payers have updated policy for code A69.21?

How do I get notified when code A69.21 policy changes?

Why do payers change policies for code A69.21?